重組細胞
expressed in baculovirus infected Sf9 cells
品質等級
產品線
PRECISIO® Kinase
化驗
≥70% (SDS-PAGE)
形狀
buffered aqueous glycerol solution
比活性
113-153 nmol/min·mg
分子量
~80 kDa
UniProt登錄號
運輸包裝
dry ice
儲存溫度
−70°C
基因資訊
human ... PTK6(5753)
生化／生理作用
BRK is a member of the non-receptor tyrosine kinases (PTKs) that contains an amino terminal SH3 and SH2 domain as well as the catalytic domain. BRK expression is low or undetectable in normal mammary tissue and benign lesions. However, approximately two-thirds of breast tumors express appreciable levels and 27% of tumors over express BRK by fivefold or more.
外觀
Supplied in 50 mM Tris-HCl, pH 7.5, with 150 mM NaCl, 0.2 5mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, and 25% glycerol.
法律資訊
PRECISIO is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
10 - Combustible liquids
水污染物質分類（WGK）
WGK 1
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)
P J Mitchell et al.
Oncogene, 15(12), 1497-1502 (1997-10-23)
The brk gene encodes a non-receptor protein tyrosine kinase that consists of single SH3, SH2 and catalytic domains. Although BRK shows strongest sequence similarity to members of the SRC family of PTKs, there are several key structural and regulatory differences
P J Mitchell et al.
Oncogene, 9(8), 2383-2390 (1994-08-01)
Using a polymerase chain reaction based differential screening approach, we have isolated and characterised a cDNA from a human metastatic breast tumour representing a novel protein tyrosine kinase (brk). Sequencing of brk cDNAs isolated from T-47D and MCF-7 human breast
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務